Last reviewed · How we verify

Magnesium sulfate IV

University of Liege · FDA-approved active Small molecule

Magnesium sulfate IV is a Electrolyte supplement / anticonvulsant Small molecule drug developed by University of Liege. It is currently FDA-approved for Seizure prophylaxis in pre-eclampsia and eclampsia, Acute asthma exacerbation (bronchodilation), Cardiac arrhythmias (particularly torsades de pointes).

Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuronal excitability and vascular smooth muscle contractility.

Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuronal excitability and vascular smooth muscle contractility. Used for Seizure prophylaxis in pre-eclampsia and eclampsia, Acute myocardial infarction with arrhythmias, Severe asthma exacerbation.

At a glance

Generic nameMagnesium sulfate IV
SponsorUniversity of Liege
Drug classElectrolyte supplement / anticonvulsant
TargetNMDA receptor, L-type calcium channels
ModalitySmall molecule
Therapeutic areaObstetrics, Neurology, Cardiology
PhaseFDA-approved

Mechanism of action

Magnesium ions compete with calcium for entry into cells and block NMDA-type glutamate receptors, thereby reducing excitatory neurotransmission. This mechanism underlies its use in preventing seizures (particularly eclampsia/pre-eclampsia), treating cardiac arrhythmias, and providing bronchodilation in acute asthma. The drug also has vasodilatory properties through effects on vascular smooth muscle.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Magnesium sulfate IV

What is Magnesium sulfate IV?

Magnesium sulfate IV is a Electrolyte supplement / anticonvulsant drug developed by University of Liege, indicated for Seizure prophylaxis in pre-eclampsia and eclampsia, Acute asthma exacerbation (bronchodilation), Cardiac arrhythmias (particularly torsades de pointes).

How does Magnesium sulfate IV work?

Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuronal excitability and vascular smooth muscle contractility.

What is Magnesium sulfate IV used for?

Magnesium sulfate IV is indicated for Seizure prophylaxis in pre-eclampsia and eclampsia, Acute asthma exacerbation (bronchodilation), Cardiac arrhythmias (particularly torsades de pointes), Hypomagnesemia replacement.

Who makes Magnesium sulfate IV?

Magnesium sulfate IV is developed and marketed by University of Liege (see full University of Liege pipeline at /company/university-of-liege).

What drug class is Magnesium sulfate IV in?

Magnesium sulfate IV belongs to the Electrolyte supplement / anticonvulsant class. See all Electrolyte supplement / anticonvulsant drugs at /class/electrolyte-supplement-anticonvulsant.

What development phase is Magnesium sulfate IV in?

Magnesium sulfate IV is FDA-approved (marketed).

What are the side effects of Magnesium sulfate IV?

Common side effects of Magnesium sulfate IV include Flushing, Hypotension, Hypermagnesemia (with overdose), Loss of deep tendon reflexes, Muscle weakness, Respiratory depression (at high doses).

What does Magnesium sulfate IV target?

Magnesium sulfate IV targets NMDA receptor, L-type calcium channels and is a Electrolyte supplement / anticonvulsant.

Related